Cancer research

Cancer Res · ISSN (print) 0008-5472 · 33 papers in corpus
2026
doi:10.1158/0008-5472.can-25-1527 ·PMID:42018149

Mitigating DNA damage in the fallopian tube epithelium (FTE) is essential for preventing tubo-ovarian high-grade serous carcinoma (HGSC). In this study, we demonstrated that the stimulator of interferon genes (STING) is abundantly expressed…

2025
doi:10.1158/0008-5472.can-25-0654 ·PMID:40658600

Subunits of the SWI/SNF chromatin remodeling complex are altered in ∼20% of human cancers. Exemplifying the alterations is the ARID1A mutation that occurs in ∼50% of ovarian clear-cell carcinoma (OCCC), a disease with limited therapeutic op…

article 2023
doi:10.1158/0008-5472.can-23-1362 ·PMID:37874327

UNLABELLED: Clear cell ovarian carcinoma (CCOC) and endometrioid ovarian carcinoma (ENOC) are ovarian carcinoma histotypes, which are both thought to arise from ectopic endometrial (or endometrial-like) cells through an endometriosis interm…

2023
doi:10.1158/0008-5472.can-22-1159 ·PMID:36354374

Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 …

2023
doi:10.1158/0008-5472.can-22-2709 ·PMID:36484700

Triple-negative breast cancer (TNBC) represents the most lethal subtype of breast cancer due to its aggressive clinical features and the lack of effective therapeutic targets. To identify novel approaches for targeting TNBC, we examined the…

other 2022
doi:10.1158/0008-5472.CAN-22-1294 ·PMID:36219681

UNLABELLED: Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem ce…

2020
doi:10.1158/0008-5472.can-19-2850 ·PMID:31932455

Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included indivi…

2019
doi:10.1158/0008-5472.can-19-0215 ·PMID:31358529

Chemoresistance is driven by unique regulatory networks in the genome that are distinct from those necessary for cancer development. Here, we investigate the contribution of enhancer elements to cisplatin resistance in ovarian cancers. Epig…

2019
doi:10.1158/0008-5472.can-17-3864 ·PMID:30487138

Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and asse…

2019
doi:10.1158/0008-5472.can-19-1554 ·PMID:31462430

Growing epidemiologic evidence supports chronic inflammation as a mechanism of ovarian carcinogenesis. An association between a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has been consistently obse…

2017
doi:10.1158/0008-5472.can-16-3322 ·PMID:28381542

Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and…

2016
doi:10.1158/0008-5472.can-15-2298 ·PMID:26685161

Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced…

2015
doi:10.1158/0008-5472.can-14-3799 ·PMID:26359457

Epithelial ovarian cancer (EOC) is the fourth leading cause of death due to cancer in women and comprises distinct histologic subtypes, which vary widely in their genetic profiles and tissues of origin. It is therefore imperative to underst…

2014
doi:10.1158/0008-5472.can-14-1706 ·PMID:25095784

Advanced technologies and biomaterials developed for tissue engineering and regenerative medicine present tractable biomimetic systems with potential applications for cancer research. Recently, the National Cancer Institute convened a Strat…

other 2014
doi:10.1158/0008-5472.CAN-13-1051 ·PMID:24272484

A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly unde…

2013
doi:10.1158/0008-5472.can-13-0241 ·PMID:23811943

Endometrial cancer is preceded by endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations, but the precise causes of endometrial cancer remain uncertain. Mig-6, mainly known as a negative regulator of the EGF receptor,…

2011
doi:10.1158/0008-5472.can-11-1562 ·PMID:21900401

ARID1A (BAF250A) promotes the formation of SWI/SNF chromatin remodeling complexes containing BRG1 or BRM. It has emerged as a candidate tumor suppressor based on its frequent mutations in ovarian clear cell and endometrioid cancers and in u…

2011
doi:10.1158/0008-5472.can-10-4102 ·PMID:21505105

Human carcinomas can metabolically incorporate and present the dietary non-human sialic acid Neu5Gc, which differs from the human sialic acid N-acetylneuraminic acid (Neu5Ac) by 1 oxygen atom. Tumor-associated Neu5Gc can interact with low l…

2011
doi:10.1158/0008-5472.can-10-3166 ·PMID:21363919

The contribution of the stromal microenvironment to the progression of endometrial cancer has not been well explored. We have conditionally expressed a mutant allele of adenomatous polyposis coli (APC(cKO)) in murine uterine stroma cells to…

2010
doi:10.1158/0008-5472.can-10-0689 ·PMID:20647319

Ovarian cancer (OC) is the single most deadly form of women's cancer, typically presenting as an advanced disease at diagnosis in part due to a lack of known risk factors or genetic markers of risk. The KRAS oncogene and altered levels of t…

2010
doi:10.1158/0008-5472.can-09-1891 ·PMID:20028871

Endometrial cancer is the most common malignancy of the lower female reproductive tract. The tumor suppressor FOXO1 is downregulated in endometrial cancer compared with normal endometrium but the underlying mechanisms are not well understoo…

other 2009
doi:10.1158/0008-5472.CAN-08-1622 ·PMID:19549922

Estrogens and selective estrogen receptor (ER) modulators such as tamoxifen are known to increase uterine cell proliferation. Mounting evidence suggests that estrogen signaling is mediated not only by ERalpha and ERbeta nuclear receptors, b…

2008
doi:10.1158/0008-5472.can-08-2592 ·PMID:19010903

Phospho-enriched protein in astrocytes (PEA-15) is a 15-kDa phosphoprotein that slows cell proliferation by binding to and sequestering extracellular signal-regulated kinase (ERK) in the cytoplasm, thereby inhibiting ERK-dependent transcrip…

2005
doi:10.1158/0008-5472.can-05-0101 ·PMID:16140938

Prostaglandins have been implicated in several neovascular diseases. In the present study, we found elevated FP receptor and vascular endothelial growth factor (VEGF) expression colocalized in glandular epithelial and vascular cells lining …

article 2000
·PMID:11156411

Loss of heterozygosity (LOH) at locus 10q23.3 and mutation of the PTEN tumor suppressor gene occur frequently in both endometrial carcinoma and ovarian endometrioid carcinoma. To investigate the potential role of the PTEN gene in the carcin…